Contrasting Patterns of Serologic and Functional Antibody Dynamics to Plasmodium falciparum Antigens in a Kenyan Birth Cohort

Clinical and Vaccine Immunology

Volumn 23, Issue 2, 2016, Pages 104-116

  Dent, Arlene E ^a,b   Malhotra, Indu ^a   Wang, Xuelie ^a   Babineau, Denise ^a,j   Yeo, Kee Thai ^b   Anderson, Timothy ^a,k   Kimmel, Rhonda J ^a   Angov, Evelina ^c   Lanar, David E ^c   Narum, David ^d   Dutta, Sheetij ^c   Richards, Jack ^e   Beeson, James G ^e,f   Crabb, Brendan S ^e   Cowman, Alan F ^g   Horii, Toshihiro ^h   Muchiri, Eric ⁱ   Mungai, Peter L ^a,i   King, Christopher L ^a   Kazura, James W ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e BURNET INSTITUTE   (Australia)

^f MONASH UNIVERSITY   (Australia)

^g WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^h OSAKA UNIVERSITY   (Japan)

ⁱ Ministry of Public Health and Sanitation   (Kenya)

^j Rho Federal Systems Division Inc   (United States)

^k UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MEROZOITE SURFACE PROTEIN 1; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

AGE; BLOOD; FEMALE; FETUS BLOOD; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; INFANT; KENYA; MALARIA, FALCIPARUM; MALE; NEWBORN; PASSIVE IMMUNIZATION; PLASMODIUM FALCIPARUM; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PRESCHOOL CHILD; SEROLOGY;

AGE FACTORS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BIOMARKERS; CHILD, PRESCHOOL; FEMALE; FETAL BLOOD; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFANT; INFANT, NEWBORN; KENYA; MALARIA, FALCIPARUM; MALE; MEROZOITE SURFACE PROTEIN 1; PLASMODIUM FALCIPARUM; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PROTOZOAN PROTEINS; SEROLOGIC TESTS;

EID: 84958639467     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00452-15     Document Type: Article

References (92)

1. Doolan DL, Dobano C, Baird JK. 2009. Acquired immunity to malaria. Clin Microbiol Rev 22:13-36. http://dx.doi.org/10.1128/CMR.00025-08.
2. Cohen S, McGregor IA, Carrington S. 1961. Gamma-globulin and ac-quired immunity to human malaria. Nature 192:733-737. http://dx.doi.org/10.1038/192733a0.
3. McGregor IA. 1964. The passive transfer of human malarial immunity. Am J Trop Med Hyg 13(Suppl): 237-239.
4. Brabin B. 1990. An analysis of malaria parasite rates in infants: 40 years after Macdonald. Trop Dis Bull 87:R1-R21.
5. Macdonald G. 1950. The analysis of malaria parasite rates in infants. Trop Dis Bull 47:915-938.
6. Riley EM, Wagner GE, Ofori MF, Wheeler JG, Akanmori BD, Tetteh K, McGuinness D, Bennett S, Nkrumah FK, Anders RF, Koram KA. 2000. Lack of association between maternal antibody and protection of African infants from malaria infection. Infect Immun 68:5856-5863. http://dx.doi.org/10.1128/IAI.68.10.5856-5863.2000.
7. Osier FH, Mackinnon MJ, Crosnier C, Fegan G, Kamuyu G, Wanaguru M, Ogada E, McDade B, Rayner JC, Wright GJ, Marsh K. 2014. New antigens for a multicomponent blood-stage malaria vaccine. Sci Transl Med 6:247ra102. http://dx.doi.org/10.1126/scitranslmed.3008705.
8. Dent AE, Nakajima R, Liang L, Baum E, Moormann AM, Sumba PO, Vulule J, Babineau D, Davies DH, Felgner PL, Kazura JW. 2015. Plasmodium falciparum protein microarray antibody profiles correlate with protection from symptomatic malaria in Kenya. J Infect Dis 212: 429-438. http://dx.doi.org/10.1093/infdis/jiv224.
9. Richards JS, Arumugam TU, Reiling L, Healer J, Hodder AN, Fowkes FJ, Cross N, Langer C, Takeo S, Uboldi AD, Thompson JK, Gilson PR, Coppel RL, Siba PM, King CL, Torii M, Chitnis CE, Narum DL, Mueller I, Crabb BS, Cowman AF, Tsuboi T, Beeson JG. 2013. Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol 191:795-809. http://dx.doi.org/10.4049/jimmunol.1300778.
10. Dobaño C, Quelhas D, Quinto L, Puyol L, Serra-Casas E, Mayor A, Nhampossa T, Macete E, Aide P, Mandomando I, Sanz S, Puniya SK, Singh B, Gupta P, Bhattacharya A, Chauhan VS, Aponte JJ, Chitnis CE, Alonso PL, Menendez C. 2012. Age-dependent IgG subclass responses to Plasmodium falciparum EBA-175 are differentially associated with incidence of malaria in Mozambican children. Clin Vaccine Immunol 19:157-166. http://dx.doi.org/10.1128/CVI.05523-11.
11. Nhabomba AJ, Guinovart C, Jimenez A, Manaca MN, Quinto L, Cistero P, Aguilar R, Barbosa A, Rodriguez MH, Bassat Q, Aponte JJ, Mayor A, Chitnis CE, Alonso PL, Dobano C. 2014. Impact of age of first exposure to Plasmodium falciparum on antibody responses to malaria in children: A randomized, controlled trial in Mozambique. Malar J 13:121. http://dx.doi.org/10.1186/1475-2875-13-121.
12. Achidi EA, Perlmann H, Salimonu LS, Perlmann P, Walker O, Asuzu MC. 1995. A longitudinal study of seroreactivities to Plasmodium falciparum antigens in Nigerian infants during their first year of life. Acta Trop 59:173-183. http://dx.doi.org/10.1016/0001-706X(95)00076-Q.
13. Kangoye DT, Nebie I, Yaro JB, Debe S, Traore S, Ouedraogo O, Sanou G, Soulama I, Diarra A, Tiono A, Marsh K, Sirima SB, Bejon P. 2014. Plasmodium falciparum malaria in children aged 0-2 years: The role of fetal haemoglobin and maternal antibodies to two asexual malaria vaccine candidates (MSP3 and GLURP). PLoS One 9:e107965. http://dx.doi.org/10.1371/journal.pone.0107965.
14. Stanisic DI, Fowkes FJ, Koinari M, Javati S, Lin E, Kiniboro B, Richards JS, Robinson LJ, Schofield L, Kazura JW, King CL, Zimmerman P, Felger I, Siba PM, Mueller I, Beeson JG. 2015. Acquisition of antibodies against Plasmodium falciparum merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response. Infect Immun 83:646-660. http://dx.doi.org/10.1128/IAI .02398-14.
15. Dent AE, Bergmann-Leitner ES, Wilson DW, Tisch DJ, Kimmel R, Vulule J, Sumba PO, Beeson JG, Angov E, Moormann AM, Kazura JW. 2008. Antibody-mediated growth inhibition of Plasmodium falciparum: Relationship to age and protection from parasitemia in Kenyan children and adults. PLoS One 3:e3557. http://dx.doi.org/10.1371/journal.pone .0003557.
16. O'Donnell RA, Saul A, Cowman AF, Crabb BS. 2000. Functional conservation of the malaria vaccine antigen MSP-119 across distantly related Plasmodium species. Nat Med 6:91-95. http://dx.doi.org/10.1038/71595.
17. Persson KE, Fowkes FJ, McCallum FJ, Gicheru N, Reiling L, Richards JS, Wilson DW, Lopaticki S, Cowman AF, Marsh K, Beeson JG. 2013. Erythrocyte-binding antigens of Plasmodium falciparum are targets of human inhibitory antibodies and function to evade naturally acquired immunity. J Immunol 191:785-794. http://dx.doi.org/10.4049/jimmunol .1300444.
18. Persson KE, Lee CT, Marsh K, Beeson JG. 2006. Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies. J Clin Microbiol 44:1665-1673. http://dx.doi.org/10.1128/JCM.44.5.1665-1673.2006.
19. Chan JA, Howell KB, Reiling L, Ataide R, Mackintosh CL, Fowkes FJ, Petter M, Chesson JM, Langer C, Warimwe GM, Duffy MF, Rogerson SJ, Bull PC, Cowman AF, Marsh K, Beeson JG. 2012. Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. J Clin Invest 122:3227-3238. http://dx.doi.org/10.1172/JCI62182.
20. Kinyanjui SM, Howard T, Williams TN, Bull PC, Newbold CI, Marsh K. 2004. The use of cryopreserved mature trophozoites in assessing antibody recognition of variant surface antigens of Plasmodium falciparuminfected erythrocytes. J Immunol Methods 288:9-18. http://dx.doi.org/10.1016/j.jim.2004.01.022.
21. Vestergaard LS, Lusingu JP, Nielsen MA, Mmbando BP, Dodoo D, Akanmori BD, Alifrangis M, Bygbjerg IC, Lemnge MM, Staalsoe T, Hviid L, Theander TG. 2008. Differences in human antibody reactivity to Plasmodium falciparum variant surface antigens are dependent on age and malaria transmission intensity in northeastern Tanzania. Infect Immun 76:2706-2714. http://dx.doi.org/10.1128/IAI.01401-06.
22. Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, Batchelor AH, Soisson L, Diggs CL, Heppner DG, Lanar DE, Collins WE, Barnwell JW. 2009. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One 4:e8138. http://dx.doi.org/10.1371/journal.pone.0008138.
23. Otsyula N, Angov E, Bergmann-Leitner E, Koech M, Khan F, Bennett J, Otieno L, Cummings J, Andagalu B, Tosh D, Waitumbi J, Richie N, Shi M, Miller L, Otieno W, Otieno GA, Ware L, House B, Godeaux O, Dubois MC, Ogutu B, Ballou WR, Soisson L, Diggs C, Cohen J, Polhemus M, Heppner DG, Jr, Ockenhouse CF, Spring MD. 2013. Results from tandem phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01. Malar J 12:29. http://dx.doi.org/10.1186/1475-2875-12-29.
24. Remarque EJ, Roestenberg M, Younis S, Walraven V, Van Der Werff N, Faber BW, Leroy O, Sauerwein R, Kocken CH, Thomas AW. 2012. Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naive adults. PLoS One 7:e38898. http://dx.doi.org/10.1371/journal.pone.0038898.
25. Singh S, Miura K, Zhou H, Muratova O, Keegan B, Miles A, Martin LB, Saul AJ, Miller LH, Long CA. 2006. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): Protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun 74:4573-4580. http://dx.doi.org/10.1128/IAI.01679-05.
26. Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, Bergmann-Leitner E, Stewart VA, Bittner S, Juompan L, Kortepeter MG, Nielsen R, Krzych U, Tierney E, Ware LA, Dowler M, Hermsen CC, Sauerwein RW, de Vlas SJ, Ofori-Anyinam O, Lanar DE, Williams JL, Kester KE, Tucker K, Shi M, Malkin E, Long C, Diggs CL, Soisson L, Dubois MC, Ballou WR, Cohen J, Heppner DG, Jr. 2009. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One 4:e5254. http://dx.doi.org/10.1371/journal.pone.0005254.
27. McCallum FJ, Persson KE, Mugyenyi CK, Fowkes FJ, Simpson JA, Richards JS, Williams TN, Marsh K, Beeson JG. 2008. Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS One 3:e3571. http://dx.doi.org/10.1371/journal.pone.0003571.
28. Crompton PD, Miura K, Traore B, Kayentao K, Ongoiba A, Weiss G, Doumbo S, Doumtabe D, Kone Y, Huang CY, Doumbo OK, Miller LH, Long CA, Pierce SK. 2010. In vitro growth-inhibitory activity and malaria risk in a cohort study in Mali. Infect Immun 78:737-745. http://dx.doi.org/10.1128/IAI.00960-09.
29. Drew DR, Hodder AN, Wilson DW, Foley M, Mueller I, Siba PM, Dent AE, Cowman AF, Beeson JG. 2012. Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria. PLoS One 7:e51023. http://dx.doi.org/10.1371/journal.pone.0051023.
30. Wilson PT, Malhotra I, Mungai P, King CL, Dent AE. 2013. Transpla-centally transferred functional antibodies against Plasmodium falciparum decrease with age. Acta Trop 128:149-153. http://dx.doi.org/10.1016/j .actatropica.2013.07.018.
31. John CC, O'Donnell RA, Sumba PO, Moormann AM, de Koning-Ward TF, King CL, Kazura JW, Crabb BS. 2004. Evidence that invasioninhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria-endemic area of Africa. J Immunol 173:666-672. http://dx.doi.org/10.4049/jimmunol .173.1.666.
32. Persson KE, McCallum FJ, Reiling L, Lister NA, Stubbs J, Cowman AF, Marsh K, Beeson JG. 2008. Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. J Clin Invest 118:342-351. http://dx.doi.org/10.1172/JCI32138.
33. Malhotra I, McKibben M, Mungai P, McKibben E, Wang X, Sutherland LJ, Muchiri EM, King CH, King CL, LaBeaud AD. 2015. Effect of antenatal parasitic infections on anti-vaccine IgG levels in children: A prospective birth cohort study in Kenya. PLoS Negl Trop Dis 9:e0003466. http://dx.doi.org/10.1371/journal.pntd.0003466.
34. Kalayjian BC, Malhotra I, Mungai P, Holding P, King CL. 2013. Marked decline in malaria prevalence among pregnant women and their offspring from 1996 to 2010 on the south Kenyan coast. Am J Trop Med Hyg 89: 1129-1134. http://dx.doi.org/10.4269/ajtmh.13-0250.
35. Malhotra I, Mungai P, Muchiri E, Ouma J, Sharma S, Kazura JW, King CL. 2005. Distinct Th1-and Th2-Type prenatal cytokine responses to Plasmodium falciparum erythrocyte invasion ligands. Infect Immun 73: 3462-3470. http://dx.doi.org/10.1128/IAI.73.6.3462-3470.2005.
36. Chatterjee S, Singh S, Sohoni R, Kattige V, Deshpande C, Chiplunkar S, Kumar N, Sharma S. 2000. Characterization of domains of the phosphoriboprotein P0 of Plasmodium falciparum. Mol Biochem Parasitol 107: 143-154. http://dx.doi.org/10.1016/S0166-6851(99)00226-1.
37. McNamara DT, Thomson JM, Kasehagen LJ, Zimmerman PA. 2004. Development of a multiplex PCR-ligase detection reaction assay for diagnosis of infection by the four parasite species causing malaria in humans. J Clin Microbiol 42:2403-2410. http://dx.doi.org/10.1128/JCM.42.6.2403-2410.2004.
38. Hillier CJ, Ware LA, Barbosa A, Angov E, Lyon JA, Heppner DG, Lanar DE. 2005. Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum. Infect Immun 73:2109-2115. http://dx.doi.org/10.1128/IAI.73.4.2109-2115.2005.
39. Porter MD, Nicki J, Pool CD, DeBot M, Illam RM, Brando C, Bozick B, De La Vega P, Angra D, Spaccapelo R, Crisanti A, Murphy JR, Bennett JW, Schwenk RJ, Ockenhouse CF, Dutta S. 2013. Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint. Clin Vaccine Immunol 20:803-810. http://dx.doi.org/10.1128/CVI.00066-13.
40. Bergmann-Leitner ES, Mease RM, De La Vega P, Savranskaya T, Polhemus M, Ockenhouse C, Angov E. 2010. Immunization with preerythrocytic antigen CelTOS from Plasmodium falciparum elicits crossspecies protection against heterologous challenge with Plasmodium berghei. PLoS One 5:e12294. http://dx.doi.org/10.1371/journal.pone .0012294.
41. Sugiyama T, Suzue K, Okamoto M, Inselburg J, Tai K, Horii T. 1996. Production of recombinant SERA proteins of Plasmodium falciparum in Escherichia coli by using synthetic genes. Vaccine 14:1069-1076. http://dx.doi.org/10.1016/0264-410X(95)00238-V.
42. Horii T, Shirai H, Jie L, Ishii KJ, Palacpac NQ, Tougan T, Hato M, Ohta N, Bobogare A, Arakaki N, Matsumoto Y, Namazue J, Ishikawa T, Ueda S, Takahashi M. 2010. Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36. Parasitol Int 59:380-386. http://dx.doi.org/10.1016/j.parint.2010.05.002.
43. Angov E, Aufiero BM, Turgeon AM, Van Handenhove M, Ockenhouse CF, Kester KE, Walsh DS, McBride JS, Dubois MC, Cohen J, Haynes JD, Eckels KH, Heppner DG, Ballou WR, Diggs CL, Lyon JA. 2003. Development and pre-clinical analysis of a Plasmodium falciparum merozoite surface protein-1(42) malaria vaccine. Mol Biochem Parasitol 128: 195-204. http://dx.doi.org/10.1016/S0166-6851(03)00077-X.
44. Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS, Hitt SL, McBride JS, Diggs CL, Holder AA, Long CA, Barnwell JW, Lyon JA. 2005. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites. Infect Immun 73:287-297. http://dx.doi.org/10.1128/IAI.73.1.287-297.2005.
45. Angov E, Hillier CJ, Kincaid RL, Lyon JA. 2008. Heterologous protein expression is enhanced by harmonizing the codon usage frequencies of the target gene with those of the expression host. PLoS One 3:e2189. http://dx.doi.org/10.1371/journal.pone.0002189.
46. Thompson JK, Triglia T, Reed MB, Cowman AF. 2001. A novel ligand from Plasmodium falciparum that binds to a sialic acid-containing receptor on the surface of human erythrocytes. Mol Microbiol 41:47-58. http://dx.doi.org/10.1046/j.1365-2958.2001.02484.x.
47. Reed MB, Caruana SR, Batchelor AH, Thompson JK, Crabb BS, Cowman AF. 2000. Targeted disruption of an erythrocyte binding antigen in Plasmodium falciparum is associated with a switch toward a sialic acidindependent pathway of invasion. Proc Natl Acad Sci U S A 97:7509-7514. http://dx.doi.org/10.1073/pnas.97.13.7509.
48. Gilberger TW, Thompson JK, Triglia T, Good RT, Duraisingh MT, Cowman AF. 2003. A novel erythrocyte binding antigen-175 paralogue from Plasmodium falciparum defines a new trypsin-resistant receptor on human erythrocytes. J Biol Chem 278:14480-14486. http://dx.doi.org/10.1074/jbc.M211446200.
49. Dutta S, Lalitha PV, Ware LA, Barbosa A, Moch JK, Vassell MA, Fileta BB, Kitov S, Kolodny N, Heppner DG, Haynes JD, Lanar DE. 2002. Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun 70:3101-3110. http://dx.doi.org/10.1128/IAI.70.6.3101-3110.2002.
50. Dutta S, Haynes JD, Barbosa A, Ware LA, Snavely JD, Moch JK, Thomas AW, Lanar DE. 2005. Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium falciparum. Infect Immun 73:2116-2122. http://dx.doi.org/10.1128/IAI .73.4.2116-2122.2005.
51. Fowkes FJ, Richards JS, Simpson JA, Beeson JG. 2010. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med 7:e1000218. http://dx.doi.org/10.1371/journal.pmed.1000218.
52. Richards JS, Stanisic DI, Fowkes FJ, Tavul L, Dabod E, Thompson JK, Kumar S, Chitnis CE, Narum DL, Michon P, Siba PM, Cowman AF, Mueller I, Beeson JG. 2010. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis 51:e50-60. http://dx.doi.org/10.1086/656413.
53. Hodder AN, Crewther PE, Anders RF. 2001. Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 69:3286-3294. http://dx.doi.org/10.1128/IAI.69.5.3286-3294.2001.
54. Miura K, Zhou H, Diouf A, Moretz SE, Fay MP, Miller LH, Martin LB, Pierce MA, Ellis RD, Mullen GE, Long CA. 2009. Anti-apicalmembrane-antigen-1 antibody is more effective than anti-42-kilodaltonmerozoite-surface-protein-1 antibody in inhibiting Plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol 16:963-968. http://dx.doi.org/10.1128/CVI.00042-09.
55. Dent AE, Moormann AM, Yohn CT, Kimmel RJ, Sumba PO, Vulule J, Long CA, Narum DL, Crabb BS, Kazura JW, Tisch DJ. 2012. Broadly reactive antibodies specific for Plasmodium falciparum MSP-1(19) are associated with the protection of naturally exposed children against infection. Malar J 11:287. http://dx.doi.org/10.1186/1475-2875-11-287.
56. Fouda GG, Leke RF, Long C, Druilhe P, Zhou A, Taylor DW, Johnson AH. 2006. Multiplex assay for simultaneous measurement of antibodies to multiple Plasmodium falciparum antigens. Clin Vaccine Immunol 13: 1307-1313. http://dx.doi.org/10.1128/CVI.00183-06.
57. Piriou E, Kimmel R, Chelimo K, Middeldorp JM, Odada PS, Ploutz-Snyder R, Moormann AM, Rochford R. 2009. Serological evidence for long-term Epstein-Barr virus reactivation in children living in a holoendemic malaria region of Kenya. J Med Virol 81:1088-1093. http://dx.doi.org/10.1002/jmv.21485.
58. Dent AE, Chelimo K, Sumba PO, Spring MD, Crabb BS, Moormann AM, Tisch DJ, Kazura JW. 2009. Temporal stability of naturally acquired immunity to merozoite surface protein-1 in Kenyan adults. Malar J 8:162. http://dx.doi.org/10.1186/1475-2875-8-162.
59. Staalsoe T, Giha HA, Dodoo D, Theander TG, Hviid L. 1999. Detection of antibodies to variant antigens on Plasmodium falciparum-infected erythrocytes by flow cytometry. Cytometry 35:329-336.
60. Beeson JG, Mann EJ, Elliott SR, Lema VM, Tadesse E, Molyneux ME, Brown GV, Rogerson SJ. 2004. Antibodies to variant surface antigens of Plasmodium falciparum-infected erythrocytes and adhesion inhibitory antibodies are associated with placental malaria and have overlapping and distinct targets. J Infect Dis 189:540-551. http://dx.doi.org/10.1086/381186.
61. Mackintosh CL, Christodoulou Z, Mwangi TW, Kortok M, Pinches R, Williams TN, Marsh K, Newbold CI. 2008. Acquisition of naturally occurring antibody responses to recombinant protein domains of Plasmodium falciparum erythrocyte membrane protein 1. Malar J 7:155. http://dx.doi.org/10.1186/1475-2875-7-155.
62. Dent AE, Yohn CT, Zimmerman PA, Vulule J, Kazura JW, Moormann AM. 2007. A polymerase chain reaction/ligase detection reaction fluorescent microsphere assay to determine Plasmodium falciparum MSP-119 haplotypes. Am J Trop Med Hyg 77:250-255.
63. Blackman MJ. 2000. Proteases involved in erythrocyte invasion by the malaria parasite: Function and potential as chemotherapeutic targets. Curr Drug Targets 1:59-83. http://dx.doi.org/10.2174/1389450003349461.
64. Holder AA, Blackman MJ, Burghaus PA, Chappel JA, Ling IT, McCallum-Deighton N, Shai S. 1992. A malaria merozoite surface protein (MSP1)-structure, processing and function. Mem Inst Oswaldo Cruz 87(Suppl 3):S37-S42.
65. Howell SA, Well I, Fleck SL, Kettleborough C, Collins CR, Blackman MJ. 2003. A single malaria merozoite serine protease mediates shedding of multiple surface proteins by juxtamembrane cleavage. J Biol Chem 278: 23890-23898. http://dx.doi.org/10.1074/jbc.M302160200.
66. Conway DJ, Cavanagh DR, Tanabe K, Roper C, Mikes ZS, Sakihama N, Bojang KA, Oduola AM, Kremsner PG, Arnot DE, Greenwood BM, McBride JS. 2000. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat Med 6:689-692. http://dx.doi.org/10.1038/76272.
67. Kaneko O, Kimura M, Kawamoto F, Ferreira MU, Tanabe K. 1997. Plasmodium falciparum: Allelic variation in the merozoite surface protein 1 gene in wild isolates from southern Vietnam. Exp Parasitol 86:45-57. http://dx.doi.org/10.1006/expr.1997.4147.
68. Kang Y, Long CA. 1995. Sequence heterogeneity of the C-terminal, Cysrich region of the merozoite surface protein-1 (MSP-1) in field samples of Plasmodium falciparum. Mol Biochem Parasitol 73:103-110. http://dx.doi.org/10.1016/0166-6851(95)00102-7.
69. Lee EA, Flanagan KL, Odhiambo K, Reece WH, Potter C, Bailey R, Marsh K, Pinder M, Hill AV, Plebanski M. 2001. Identification of frequently recognized dimorphic T-cell epitopes in Plasmodium falciparum merozoite surface protein-1 in West and East Africans: Lack of correlation of immune recognition and allelic prevalence. Am J Trop Med Hyg 64:194-203.
70. Osier FH, Weedall GD, Verra F, Murungi L, Tetteh KK, Bull P, Faber BW, Remarque E, Thomas A, Marsh K, Conway DJ. 2010. Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya. Infect Immun 78:4625-4633. http://dx.doi.org/10.1128/IAI.00576-10.
71. Amaratunga C, Lopera-Mesa TM, Brittain NJ, Cholera R, Arie T, Fujioka H, Keefer JR, Fairhurst RM. 2011. A role for fetal hemoglobin and maternal immune IgG in infant resistance to Plasmodium falciparum malaria. PLoS One 6:e14798. http://dx.doi.org/10.1371/journal.pone .0014798.
72. D'Alessandro U, Ubben D, Hamed K, Ceesay SJ, Okebe J, Taal M, Lama EK, Keita M, Koivogui L, Nahum A, Bojang K, Sonko AA, Lalya HF, Brabin B. 2012. Malaria in infants aged less than 6 months: Is it an area of unmet medical need? Malar J 11:400. http://dx.doi.org/10.1186/1475-2875-11-400.
73. Kassim OO, Ako-Anai KA, Torimiro SE, Hollowell GP, Okoye VC, Martin SK. 2000. Inhibitory factors in breastmilk, maternal and infant sera against in vitro growth of Plasmodium falciparum malaria parasite. J Trop Pediatr 46:92-96. http://dx.doi.org/10.1093/tropej/46.2.92.
74. Jaspan HB, Lawn SD, Safrit JT, Bekker LG. 2006. The maturing immune system: Implications for development and testing HIV-1 vaccines for children and adolescents. AIDS 20:483-494. http://dx.doi.org/10.1097/01 .aids.0000210602.40267.60.
75. Duah NO, Miles DJ, Whittle HC, Conway DJ. 2010. Acquisition of antibody isotypes against Plasmodium falciparum blood stage antigens in a birth cohort. Parasite Immunol 32:125-134. http://dx.doi.org/10.1111/j .1365-3024.2009.01165.x.
76. White MT, Griffin JT, Akpogheneta O, Conway DJ, Koram KA, Riley EM, Ghani AC. 2014. Dynamics of the antibody response to Plasmodium falciparum infection in African children. J Infect Dis 210:1115-1122. http://dx.doi.org/10.1093/infdis/jiu219.
77. Collins CR, Withers-Martinez C, Bentley GA, Batchelor AH, Thomas AW, Blackman MJ. 2007. Fine mapping of an epitope recognized by an invasion-inhibitory monoclonal antibody on the malaria vaccine candidate apical membrane antigen 1. J Biol Chem 282:7431-7441.
78. Feng ZP, Keizer DW, Stevenson RA, Yao S, Babon JJ, Murphy VJ, Anders RF, Norton RS. 2005. Structure and inter-domain interactions of domain II from the blood-stage malarial protein, apical membrane antigen 1. J Mol Biol 350:641-656. http://dx.doi.org/10.1016/j.jmb.2005.05.011.
79. Mutapi F, Roussilhon C, Mduluza T, Druilhe P. 2007. Anti-malaria humoral responses in children exposed to Plasmodium falciparum and Schistosoma haematobium. Mem Inst Oswaldo Cruz 102:405-409. http://dx.doi.org/10.1590/S0074-02762007005000046.
80. Roussilhon C, Oeuvray C, Muller-Graf C, Tall A, Rogier C, Trape JF, Theisen M, Balde A, Perignon JL, Druilhe P. 2007. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med 4:e320. http://dx.doi.org/10.1371/journal.pmed.0040320.
81. Tongren JE, Drakeley CJ, McDonald SL, Reyburn HG, Manjurano A, Nkya WM, Lemnge MM, Gowda CD, Todd JE, Corran PH, Riley EM. 2006. Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria. Infect Immun 74:257-264. http://dx.doi.org/10.1128/IAI.74.1.257-264.2006.
82. Hviid L, Staalsoe T. 2004. Malaria immunity in infants: A special case of a general phenomenon? Trends Parasitol 20:66-72. http://dx.doi.org/10.1016/j.pt.2003.11.009.
83. Marsh K, Howard RJ. 1986. Antigens induced on erythrocytes by P. falciparum: Expression of diverse and conserved determinants. Science 231:150-153. http://dx.doi.org/10.1126/science.2417315.
84. Reeder JC, Rogerson SJ, al-Yaman F, Anders RF, Coppel RL, Novakovic S, Alpers MP, Brown GV. 1994. Diversity of agglutinating phenotype, cytoadherence, and rosette-forming characteristics of Plasmodium falciparum isolates from Papua New Guinean children. Am J Trop Med Hyg 51:45-55.
85. Kinyanjui SM, Bull P, Newbold CI, Marsh K. 2003. Kinetics of antibody responses to Plasmodium falciparum-infected erythrocyte variant surface antigens. J Infect Dis 187:667-674. http://dx.doi.org/10.1086/373994.
86. Blackman MJ, Heidrich HG, Donachie S, McBride JS, Holder AA. 1990. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med 172:379-382. http://dx.doi.org/10.1084/jem.172.1.379.
87. Tham WH, Healer J, Cowman AF. 2012. Erythrocyte and reticulocyte binding-like proteins of Plasmodium falciparum. Trends Parasitol 28:23-30. http://dx.doi.org/10.1016/j.pt.2011.10.002.
88. Dent A, Malhotra I, Mungai P, Muchiri E, Crabb BS, Kazura JW, King CL. 2006. Prenatal malaria immune experience affects acquisition of Plasmodium falciparum merozoite surface protein-1 invasion inhibitory antibodies during infancy. J Immunol 177:7139-7145. http://dx.doi.org/10.4049/jimmunol.177.10.7139.
89. Boyle MJ, Reiling L, Feng G, Langer C, Osier FH, Aspeling-Jones H, Cheng YS, Stubbs J, Tetteh KK, Conway DJ, McCarthy JS, Muller I, Marsh K, Anders RF, Beeson JG. 2015. Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity 42:580-590. http://dx.doi.org/10.1016/j.immuni.2015.02.012.
90. Osier FH, Feng G, Boyle MJ, Langer C, Zhou J, Richards JS, McCallum FJ, Reiling L, Jaworowski A, Anders RF, Marsh K, Beeson JG. 2014. Opsonic phagocytosis of Plasmodium falciparum merozoites: Mechanism in human immunity and a correlate of protection against malaria. BMC Med 12:108. http://dx.doi.org/10.1186/1741-7015-12-108.
91. Ambroggio X, Jiang L, Aebig J, Obiakor H, Lukszo J, Narum DL. 2013. The epitope of monoclonal antibodies blocking erythrocyte invasion by Plasmodium falciparum map to the dimerization and receptor glycan binding sites of EBA-175. PLoS One 8:e56326. http://dx.doi.org/10.1371/journal.pone.0056326.
92. Srinivasan P, Ekanem E, Diouf A, Tonkin ML, Miura K, Boulanger MJ, Long CA, Narum DL, Miller LH. 2014. Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria. Proc Natl Acad Sci U S A 111:10311-10316. http://dx.doi.org/10.1073/pnas.1409928111.